Induced Hypoglycemic Treatment

Induced Hypoglycemic Treatment – evaluation of procedure offered by BioPulse International

A case of case histories leading to trouble

Induced Hypoglycemic Treatment (IHT) is one of several cancer-treatment methods offered by BioPulse International, which operates clinics in Mexico and Germany and plans to open additional facilities elsewhere. The company’s Web site states that IHT uses a regulated level of insulin and other medications to induce a sleeping state during which the attending physician “regulates blood oxygen levels, body temperature, and pH levels to target the cancerous tumors.” The sessions normally last about an hour.

The “BioPulse program with IHT” costs $5,000 per week for the first four weeks and $3,500 per week thereafter. The program usually includes “detoxification” with colonic irrigation; intravenous infusions of vitamin, minerals, amino acids, and enzymes; oral supplements; dietary strategies; and referral to “biological dentists” to remedy alleged problems caused by amalgam fillings and root canals. A four-week program that includes one session of whole-body hyperthermia (an unsubstantiated treatment in which the body’s temperature is temporarily raised to 106 [degrees] F) costs $24,000. The sleep sessions are usually done once a day, five days a week, for three to seven weeks. Advance payment is required.

IHT is claimed to work by (a) starving cancer cells of glucose; (b) raising the blood pH to an alkaline state that is hostile to tumors; (c) increasing blood oxygen saturation, which prevents “anaerobic” tumor cells from thriving; (d) cleansing the body through sweating; and (e) restoring the body’s energy levels and increasing appetite. However, this rationale is not logical.

(a) Cancer cells cannot be selectively “starved” by lowering blood sugar.

If blood sugar is lowered tar enough to damage cells, the body’s brain

cells would be among the first casualties. Hypoglycemic episodes are fairly

common among diabetics who take insulin, including diabetics who have

cancer. If hypoglycemia could selectively kill cancer cells, it stands to

reason that diabetics would have a lower incidence of cancer as well as a

higher recovery rate. But neither of these has been detected.

(b) The body’s self-regulatory mechanisms keep blood pH within a narrow

range. This range is not regulated by insulin. Even if insulin could raise

the blood pH, it would have no effect on any cancer.

(c) Blood oxygen saturation is not regulated by insulin. Nor are tumors

anaerobic. The theory that tumor cells thrive when oxygen-deprived was

discredited more than fifty years ago. Growth requires both nutrients and

oxygen. Solid tumors require more because they grow faster than the

corresponding normal cells.

(d) The main substance excreted in sweat is sodium chloride (table

salt), which is why sweat tastes salty. Most chemical waste products are

excreted by the liver and kidneys. Increasing perspiration does not

“detoxify” the body. Nor is there any valid reason to believe that

“accumulated toxins” are responsible for the majority of cancers or that

removing such alleged chemicals would be therapeutic.

(e) Hypoglycemic episodes are usually followed by several hours of

depressed functioning. Many factors can influence how energetic people

feel. Giving seriously ill cancer patients new hope, for example, may make

them feel better–and more energetic. But if the hope proves false, the

good feeling will quickly disappear.

The BioPulse site includes skimpy case histories of four people who apparently believe that IHT was highly effective against their cancers, but the reports were made only a few months after the treatment was administered. Three of the patients have also had standard treatment. Three of the reports state that the patients still have evidence of cancer but claim to have improved or stabilized. The standard way to report cancer-treatment outcome is to collect detailed data for at least five years and to follow enough patients to determine whether the outcome is better than would be expected from other treatment or from the natural course of the disease. Treatment effectiveness cannot be judged from anecdotes, testimonials, skimpy case reports, or short-term follow-up. BioPulse began doing IHT in June 1999 and reported “outstanding results” less than three months later. The results were announced at the annual convention of the Cancer Control Society and in a cover story in Alternative Medicine Digest.

Insulin-coma treatment (also called “insulin shock”) was legitimately used to treat schizophrenia beginning in the 1930s. Its use declined after electroconvulsive treatment was developed, and it was abandoned, beginning in the 1950s, as a potent antipsychotic drugs became available. Permanent measurable complications are rare but have included memory impairment, reduced intelligence, strokes, abnormal heart rhythms, and even death. The Alternative Medicine Digest report states that BioPulse’s sleep treatment is aimed to lower the patient’s blood-sugar levels to “20 mg/dL or below,” which is extremely low. Although Biopulse reports no complications so far, insulin coma should not be regarded as risk-free.

COPYRIGHT 2000 Prometheus Books, Inc.

COPYRIGHT 2000 Gale Group